Risk Management Documentation Requirements for Overseas Registration of Disinfection and Sterilization Equipment

Risk Management Documentation Requirements for Overseas Registration of Disinfection and Sterilization Equipment

Published: August 28, 2026, 16:51. Updated: August 28, 2026, 16:51

For overseas registration of disinfection and sterilization equipment, the risk management documentation is the most commonly corrected section due to misunderstandings. Manufacturers must first determine whether the target country regulates the product as a medical device, and then determine the registration pathway and applicant entity based on the product's intended use and risk classification. In GHWP member markets, a risk management file compliant with ISO 14971 is typically required, covering a complete evidence chain from risk analysis, risk evaluation, and risk control to overall residual risk evaluation. Additionally, the links between the risk management report and the product technical file, performance verification reports, and clinical evaluation or exemption rationale must be established. Specific risks, such as software-related risks, biocompatibility risks, and sterilization process failure risks, must be addressed. Warning statements and contraindication content in labels and instructions for use must align with the risk management conclusions. Manufacturers should confirm with the local agent or authorized representative the responsibilities for documentation retention, change notification, and post-market surveillance, and maintain the risk documentation throughout the certificate validity period. Most audit failures are due to risk control measures not being supported by verification results, failure to consider reasonably foreseeable misuse, omission of compliance risks, and unclear risk acceptability criteria. It is recommended that manufacturers structure the risk documentation developed during the NMPA, CE, or FDA stages and localize it to the target country's format requirements rather than simply submitting a translated copy.

This FAQ article addresses priority issues that project teams need to consider in medical device international registration, documentation preparation, compliance pathways, and post-market maintenance.

This article is compiled based on the AIMEILI registration practice question bank, the medical device international registration knowledge base, and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authorities and the product documentation.

Key Points

When registering disinfection and sterilization equipment overseas, the risk management documentation is the section most prone to repeated deficiency responses due to misunderstandings. Manufacturers must first determine whether the target country regulates the product as a medical device, then select the registration pathway and applicant entity according to the intended use and risk classification. In GHWP member markets, a risk management file meeting ISO 14971 requirements is usually needed, with a complete chain of evidence covering risk analysis, risk evaluation, risk control, and overall residual risk evaluation.

Moreover, the risk management report must be clearly connected with the product technical file, performance verification reports, and clinical evaluation or exemption rationale. Specific topics such as software-related risks, biocompatibility risks, and sterilization process failure risks should be covered. Warning statements and contraindications in labeling and instructions for use must be consistent with the risk management conclusions. Manufacturers should confirm with the local agent or authorized representative the responsibilities for maintaining the risk documentation, communicating changes, and performing post-market surveillance, and must keep the risk documentation current while the certificate is valid.

Most audit rejections are attributed to the disconnection between risk control measures and verification results, failure to consider actual use errors, omission of compliance risks, and unclear risk acceptability criteria. It is recommended that manufacturers systematically organize the risk documentation generated during the NMPA, CE, or FDA stages and localize it according to the target country's format requirements instead of relying on direct translation.

Applicable Scenarios and Core Issues

For overseas registration of disinfection and sterilization equipment, the core question is not whether risk management is required but how detailed the risk management documentation must be to pass the local review. These products may include steam sterilizers (autoclaves), ethylene oxide sterilizers, low-temperature plasma sterilizers, hydrogen peroxide sterilizers, and endoscope washers/disinfectors. Because these products differ significantly in working principles, use environments, and operator profiles, regulators may apply different levels of scrutiny to the risk management documentation.

From the project initiation stage, manufacturers must confirm the medical device definition and classification rules in the target country. Some disinfection and sterilization equipment is classified as Class II or Class IIa, while others may fall into Class III or Class IIb. The classification determines the formality and review rigor of the risk management file. For example, in most GHWP member countries in Southeast Asia, based on the ASEAN Medical Device Directive or national regulations, a risk management summary that follows the IMDRF or ISO 14971 reference framework is often required.

It is also necessary to determine whether the product is a combination product. If the equipment uses chemical sterilants or includes software, sensors, or alarm systems, additional evaluation is required for chemical exposure risks, cybersecurity risks, electromagnetic compatibility, and usability-related risks. If these aspects are not reflected in the risk management documentation, the review authority will issue a deficiency notice.

Another frequently overlooked issue is that manufacturers often treat the risk management report as a standalone document, ignoring its logical relationships with the product technical file, test reports, instructions for use, and clinical evaluation. In fact, the risk management file is the backbone of the registration dossier: all verification and validation activities should be driven by risk analysis, and in turn, verification results should update the risk evaluation.

Registration Decision Logic

Step 1: Determine whether the product falls within the target country's medical device regulatory scope. Some disinfection and sterilization equipment may be considered general laboratory equipment or products used together with medical devices, and may not require registration or may only need to meet electrical safety standards. Manufacturers should verify this through the official product classification database or through an inquiry with the local agent or regulatory consultant.

Step 2: Determine the product risk class and registration pathway. In GHWP member countries such as Malaysia, Thailand, Vietnam, and the Philippines, classification usually follows GHTF rules or ASEAN harmonized documents. Products in Class II and above generally require submission of risk assessment, clinical evaluation, or performance verification documents, and some countries also require factory audits.

Step 3: Assess whether existing data can be reused. If the product already has an NMPA registration certificate or a CE certificate, the existing risk management documentation, performance verification data, biocompatibility tests, and software lifecycle documents can serve as a basis. However, it must be confirmed whether the target country accepts these data and whether local language versions or additional tests are required.

Step 4: Confirm the legal responsibilities of the local agent and authorized representative. In most countries, the local agent is not only responsible for retaining the technical file but also for adverse event reporting, on-site update terms, and change notifications. The risk management documentation must state the agent's contact information, file update procedures, and post-market surveillance interfaces; otherwise, this will be cited as a deficiency during review.

Documentation and Evidence

The risk management documentation generally must include the following core components: risk management plan, risk analysis, risk evaluation, risk control measures, overall residual risk evaluation, and risk management report. Each part must have specific inputs and outputs and indicate the document version, preparation date, and responsible person.

In the risk analysis section, scenarios to be covered include normal use, reasonably foreseeable misuse, fault conditions, transportation and storage conditions, and abnormal sterilization process conditions. Appropriate analysis methods such as FMEA, FTA, or HAZOP should be used, with documented justification for severity, probability of occurrence, and detectability ratings.

In the risk control section, the source of each risk control measure must be stated, whether it is a design change, a protective device, or safety information. For each control measure, corresponding verification or validation evidence should be provided, such as test reports, risk assessment experimental data, software verification records, or instructions for use rationale.

For disinfection and sterilization equipment, additional sterilization process qualification documentation is required. Whether based on ISO 11135, ISO 11137, or ANSI/AAMI ST50, these process qualification documents must be linked to the sterilization failure risks identified in the risk management file. If the equipment is intended for hospital sterilization rooms, loading patterns, drying phases, environmental emissions, and operator protection should also be considered.

Warning statements, contraindications, and restrictions in the labeling and instructions for use must be fully consistent with the risk management file. Many manufacturers are cited during registration review because certain warning statements in the instructions for use have no source in the risk management report, or because the safety warnings claimed as risk control measures are not reflected on the label. These issues should be checked item by item before submission.

If the product contains software, such as an integrated control system or remote diagnostic module, software development process and risk analysis records must be provided in accordance with IEC 62304, combined with usability engineering assessment results under IEC 62366.

For the GHWP member country markets, manufacturers should also prepare local language versions of the risk management documentation and declarations of conformity. Some countries require translation into the official local language and signature by the local agent, for example in Indonesian, Thai, or Vietnamese. This step is often overlooked, resulting in language consistency review deficiencies after submission.

Common Mistakes

• Directly reusing risk management reports from NMPA or CE submissions without identifying target-country regulatory differences and review priorities.
• Disconnection between the risk management report and the product technical requirements or test report parameters, such as inconsistent sterilization temperature ranges, probe positions, and tolerance values.
• Vague risk acceptability criteria without quantitative or qualitative thresholds, making it impossible for reviewers to judge whether risks are acceptable.
• Analyzing only the risk of sterilization failure while ignoring chemical residues, mechanical hazards, electrical hazards, radiation hazards, noise, and ergonomic hazards.
• Failure to link the post-market surveillance plan with risk management updates, including unclear information collection channels, evaluation frequency, and triggers for initiating corrective action.
• Missing analysis of local regulatory compliance risks, such as differences in supply voltage, environmental temperature/humidity, language, and operating habits in the target country.
• Authorized representative responsibilities not described in the risk management documentation, or no local agent control over risk documentation retention and version control.
• References to withdrawn standards, or no indication of the published date or applicable clause of the referenced standard.

Preparation Checklist

• Confirm the device classification and registration pathway in the target country, and retain the basis for the classification determination.
• Establish a risk management plan that defines risk acceptability criteria, team responsibilities, review milestones, and documentation output requirements.
• Collect all intended uses, operating environments, target populations, and contraindication scenarios as inputs for risk analysis.
• Organize existing design validation, performance testing, biocompatibility testing, software verification, and sterilization process qualification reports and map them to individual risk control measures.
• Build a complete risk file based on ISO 14971 and prepare a short risk management summary to facilitate rapid review.
• Check that warning information in the labeling, instructions for use, and packaging is consistent with the safety information in the risk management report.
• Sign an agreement with the local agent or authorized representative defining their responsibilities in registration submission, document retention, change notification, and post-market surveillance.
• Develop a post-market surveillance plan that includes adverse event reporting, customer complaint analysis, periodic risk re-evaluation, and risk documentation update procedures.
• Before submission, conduct an internal pre-review with an experienced regulatory advisor to simulate potential reviewer questions on the risk management documentation.

AIMEILI Insights

Manufacturers often mistakenly believe that the risk management documentation only needs to satisfy formal requirements. In reality, review authorities will trace whether risk control measures are truly supported by data. Do not simply write vague descriptions such as 'ensured by design' or 'added alarm prompts.' Instead, attach the corresponding verification report numbers, test conclusions, and residual risk evaluations.

In the early stage of a project, spend one to two weeks identifying the gaps between existing risk documentation and target-country requirements, rather than rushing to translate the entire dossier. Focus risk management efforts on high-priority risks based on product classification and local regulations, such as sterilant residues, operator safety, and infection risks caused by sterilization failure.

Core reusable documents include FMEAs, safety standard test data, biocompatibility reports, and software lifecycle documents. However, risk acceptability criteria, label and instruction wording, authorized representative sections, regulatory compliance risk analysis, and post-market surveillance procedures must be localized.

The local agent is not simply a stamp and signature. Many countries require the local agent to have legal custody of the technical file. If the agent changes or the original risk documentation cannot be accessed at certificate renewal, the registration certificate may not be successfully renewed. The contract should clearly define version control, access rights, and change notification timeframes for the risk management documentation.

For multi-country registrations, it is strongly recommended that manufacturers establish a structure of 'master risk management document plus country-specific difference annexes.' The master document should be prepared based on ISO 14971 and major market requirements, while the difference annexes record specific national rules, translation versions, and local agent information. This approach significantly reduces duplicate efforts and deficiency response risks and ensures consistency across multiple country submissions.

Frequently Asked Questions

Question 1: Is a standalone risk management report required for disinfection and sterilization equipment?

In most countries, especially GHWP member states, the review authority will require a standalone risk management report or risk management summary. This report should consolidate risk analysis, risk evaluation, risk control, overall residual risk evaluation, and risk acceptability conclusions, and reference the detailed records in the annexes. Even if a standalone report is not mandatory in some countries, it is advisable to prepare one because it significantly reduces review communication effort.

Question 2: Can existing risk management documentation continue to be used after an update to ISO 14971?

If the target country explicitly cites a specific version of ISO 14971, manufacturers must verify whether the existing documentation meets the new version's requirements. In general, ISO 14971:2019 emphasizes management commitment, lifecycle perspective, and the ongoing nature of risk control measures. A gap analysis is needed, especially for content related to reasonably foreseeable misuse and safety information. Also, note that different markets may have varying acceptance of standard versions.

Question 3: Can a risk management file be used to exempt clinical evaluation if complete clinical evaluation data are not available?

For certain disinfection and sterilization equipment, when the product meets general safety and performance requirements and no unacceptable risks exist, a clinical exemption rationale under risk management may be used instead of a clinical trial. However, the basis for the exemption must be clearly stated, such as equivalence comparison, non-direct patient contact, or a long history of safe use. When preparing the exemption rationale, the risk analysis in the risk management file should be combined with literature data, usage data, and adverse event data; it is not acceptable to simply state 'no clinical evaluation required.'

Related Reading

Previous article: How should multiple models of disinfection and sterilization equipment be grouped for overseas registration?

Next article: How should registration documentation for medical dressings be prepared for overseas registration?

Recommended reading:

• Requirements for risk management documentation for overseas registration of software medical devices
• Requirements for risk management documentation for overseas registration of POCT products
• Requirements for risk management documentation for overseas registration of medical devices
• How should multiple models of implantable products be grouped for overseas registration?
• Why does the registration cycle for laboratory equipment overseas often extend?
• How should a local agent be selected for overseas registration of disinfection and sterilization equipment?

Return to FAQ Center | News | Contact AIMEILI

Content Review and Applicability Boundaries

Author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Group

Source principles: Priority is given to official regulatory agencies, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience are used only as supplementary references.

Applicability boundary: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of the target country's regulatory authority, test conclusions, or legal opinions.